MabGenesis is a biopharmaceutical startup company that offers therapeutic monoclonal antibody drugs for both humans and companion animals.
MabGenesis has raised $3.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2024.
MabGenesis's investors include SMBC Venture Capital, Beyond Next Ventures, Miyazaki Taiyo Capital, Axil Capital, ANNIVERSAIRE.
MabGenesis is headquartered in Yokohama, Japan.
MabGenesis is a biopharmaceutical startup company that offers therapeutic monoclonal antibody drugs for both humans and companion animals.
MabGenesis is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MabGenesis — Funding & Investors." VCBacked, December 24, 2024, https://www.vcbacked.co/company/mabgenesis. Accessed September 2, 2026.
VCBacked. (2024). MabGenesis — Funding & Investors. Retrieved September 2, 2026, from https://www.vcbacked.co/company/mabgenesis
{{cite web |title=MabGenesis — Funding & Investors |url=https://www.vcbacked.co/company/mabgenesis |website=VCBacked |access-date=September 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated